mixngo the disruptive technology, page-18

Hey Smilez

I dont think your off topic

Have a close look at Quanterix website and join the dots

http://www.quanterix.com/applications/ad.html

For the first time, using Quanterixs SiMoA technology, it is now possible to detect these same proteins with a simple blood test, even though they are present in the blood at exceedingly low concentrations, well below the limit of detection achieved by standard testing methods. Quanterix is developing an Alzheimers Disease test panel that will enable rule in diagnosis of AD from a simple blood test, eliminating the need for invasive medical procedures, shortening time to diagnosis, and reducing the use of expensive imaging modalities. Quanterix has entered into clinical collaborations to validate that the changing levels of these biomarkers track with disease progression.

Selected biomarkers from this test panel may also have clinical utility in diagnosing other neurological disorders including Parkinsons disease, bipolar disorder, stroke and traumatic brain injury (TBI).